ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0400

Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Abstract Number: 0401

Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
Abstract Number: 0402

Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts
Abstract Number: 0403

Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process
Abstract Number: 0404

Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData
Abstract Number: 0405

Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Abstract Number: 0406

Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis
Abstract Number: 0407

Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India
Abstract Number: 0408

Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Abstract Number: 0409

Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Abstract Number: 0410

Efficacy of Modified Dosing/interval Timing of Adalimumab in Patients Affected by Chronic Non Infectious Uveitis: A Retrospective Monocentric Study
Abstract Number: 0411

Axial Radiographic Structural Damage in Enthesitis-Related Arthritis in Children and Young Adult Patients
Abstract Number: 0412

Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Abstract Number: 0413

Efficacy of Intra-articular Glucocorticoids as a Treatment for Oligoarticular Juvenile Idiopathic Arthritis: A Bicentric Retrospective Study in Japan
Abstract Number: 0414

Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].